Global Atopic Dermatitis Drugs Market | Trends, Analysis, Forecast 2019-2027

1
Atopic Dermatitis Market
FORECAST 2019-2027
2
(No Transcript)
3

• The Atopic Dermatitis Drugs global market is
  growing at 4.66 of CAGR over the forecasting
  years.
• Growing incidences of allergies due to particular
  foods is the major factor augmenting the market
  growth globally.

4

• Atopic Dermatitis is a skin disease also known as
  chronic eczematous. The symptoms of this disease
  vary person to person. However, some of its
  common symptoms are inflamed and itchy skin that
  causes crackling, minute blisters, swelling,
  scaling, and crusting.
• The global Atopic Dermatitis drugs market
  comprise of two segments route of administration
  and drug class.
• The topical segment holds the highest share in
  the Atopic Dermatitis Drugs route of
  administration market.
• The interleukin inhibitor segment is anticipated
  to generate the highest revenue in the Atopic
  Dermatitis drug class market.
• The global Atopic Dermatitis Drugs market is
  highly generic which creates a lot of challenges
  in the growth of the market globally.

5
(No Transcript)
6
The Atopic Dermatitis Drugs global market is
growing at 4.66 of CAGR over the forecasting
years.
7
During the forecasting years, the Atopic
Dermatitis Drugs market in North America is
proliferating at a CAGR of 4.06.
8
Europe Atopic dermatitis drugs market continues
to escalate at 3.20 of CAGR over the forecasting
years.
9
The Atopic Dermatitis Drugs market in APAC region
is anticipated to evolve at a CAGR of 7.46 over
the estimated period 2018-2026.
10
The established players in the market are
Allergan Plc., Aqua Pharmaceuticals (An Almirall
Company), Astellas Pharma Inc., Bayer Ag,
Biofrontera Ag, Bristol-Myers Squibb, Stiefel
Laboratories Inc., Encore Dermatology, Galderma
Sa, Leo Pharma, Meda Pharmaceuticals (Mylan),
Novartis Ag, Pfizer, Regeneron Pharmaceuticals,
Sanofi Sa, and Valent Pharmaceutical Inc.
11
(No Transcript)
12
(No Transcript)
13
(No Transcript)